High Court Won’t Hear Dispute Over Patented Schizophrenia Drug
WASHINGTON, D.C. — In its Jan. 13 order list, the U.S. Supreme Court rejected a petition for certiorari that poses the question of whether method-of-treatment patent claims automatically satisfy Section 101...To view the full article, register now.
Already a subscriber? Click here to view full article